Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Stock Short Interest Report for October

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the recipient of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 4,226 shares, a decrease of 92.6% from the October 15th total of 57,367 shares. Based on an average daily volume of 50,823 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Otsuka Stock Performance

Shares of Otsuka stock traded up $0.09 during midday trading on Wednesday, hitting $37.77. The company had a trading volume of 2,465 shares, compared to its average volume of 41,222. The stock has a market cap of $40.57 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.75 and a beta of 0.08. The company has a quick ratio of 1.65, a current ratio of 2.21 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $37.29 and a 200 day simple moving average of $35.15. Otsuka has a 12-month low of $26.11 and a 12-month high of $40.92.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Friday, October 30th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. The company had revenue of $4.51 billion for the quarter, compared to the consensus estimate of $4.42 billion. As a group, analysts predict that Otsuka will post 2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded Otsuka from a “strong-buy” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.